Page last updated: 2024-12-11

rg 14620

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

RG 14620: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	5353928
CHEBI ID	92393
SCHEMBL ID	7531602
MeSH ID	M0191433

Synonyms (33)

Synonym
136831-49-7
rg 14620
(e)-3-(3,5-dichlorophenyl)-2-pyridin-3-ylprop-2-enenitrile
SCHEMBL7531602
tyrphostin rg 14620
S6523
3-(3,5-dichlorophenyl)-2-(pyridin-3-yl)prop-2-enenitrile
3-pyridineacetonitrile,a-[(3,5-dichlorophenyl)methylene]-
CHEBI:92393
tyrphostin rg 14620, >=98%
J-006920
rg14620
HY-101426
CS-6334
(e)-3-(3,5-dichlorophenyl)-2-(pyridin-3-yl)acrylonitrile
2-(3',5'-dichlorophenyl)-1-(3''-pyridinyl)acrylonitrile
rg14620; rg-14620; tyrphostin rg 14620
BCP20770
mfcd00236445
tyrphostin rg14620
3-pyridineacetonitrile, .alpha.-((3,5-dichlorophenyl)methylene)-, (e)-
N17031
AS-57195
AKOS037645108
AKOS037515517
tyrphostinrg14620
138989-56-7
unii-zzl6fh3xrc
3-pyridineacetonitrile, alpha-((3,5-dichlorophenyl)methylene)-, (e)-
rg-14620, (e)-
rpr-100619
ZZL6FH3XRC ,
(2e)-3-(3,5-dichlorophenyl)-2-(pyridin-3-yl)prop-2-enenitrile

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	3 (42.86)	18.2507
2000's	2 (28.57)	29.6817
2010's	2 (28.57)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.25 (24.57)
Research Supply Index	2.20 (2.92)
Research Growth Index	4.45 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.25)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	8 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
quinazolines Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.	2.01	1	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines
alkenes [no description available]	1.98	1
sb 203580 [no description available]	2.05	1	imidazoles; monofluorobenzenes; pyridines; sulfoxide	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector; Hsp90 inhibitor; neuroprotective agent
tretinoin Tretinoin: An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE).. retinoic acid : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraenoic acid substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified).. all-trans-retinoic acid : A retinoic acid in which all four exocyclic double bonds have E- (trans-) geometry.	2.01	1	retinoic acid; vitamin A	anti-inflammatory agent; antineoplastic agent; antioxidant; AP-1 antagonist; human metabolite; keratolytic drug; retinoic acid receptor agonist; retinoid X receptor agonist; signalling molecule
sirolimus Sirolimus: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.. sirolimus : A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.	2.46	2	antibiotic antifungal drug; cyclic acetal; cyclic ketone; ether; macrolide lactam; organic heterotricyclic compound; secondary alcohol	antibacterial drug; anticoronaviral agent; antineoplastic agent; bacterial metabolite; geroprotector; immunosuppressive agent; mTOR inhibitor
rg 13022 RG 13022: structure given in first source	2.38	2
tyrphostin ag825 tyrphostin AG825: a tyrphostin of the benzylidene malononitrile family; an erbB2 antagonist. tyrphostin AG 825 : An organic sulfide that consists of 1,3-benzothiazole-2-thiol in which the hydrogen attached to the sulfur atom is replaced by a 5-[(1E)-3-amino-2-cyano-3-oxoprop-1-en-1-yl]-2-hydroxy-3-methoxybenzyl group. It acts as an epidermal growth factor receptor antagonist.	2.01	1	aromatic ether; benzothiazoles; enamide; nitrile; organic sulfide; phenols; primary carboxamide	epidermal growth factor receptor antagonist
zm 252868 PD-153035 hydrochloride : A hydrochloride obtained by combining PD-153035 with one equivalent of hydrochloric acid.	2.01	1	hydrochloride	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; epidermal growth factor receptor antagonist
ag-879 AG-879: structure given in first source	2.01	1

Condition	Relationship Strength	Studies
Benign Neoplasms [description not available]	2.15	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	2.15	1
Cancer of Endometrium [description not available]	2.46	2
Endometrial Neoplasms Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.	2.46	2
Adenocarcinoma, Basal Cell [description not available]	2.01	1
Cancer of Ovary [description not available]	2.01	1
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	2.01	1
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	2.01	1
Bladder Cancer [description not available]	1.98	1
Adenocarcinoma Of Kidney [description not available]	1.98	1
Cancer of Kidney [description not available]	1.98	1
Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER.	1.98	1
Carcinoma, Renal Cell A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.	1.98	1
Kidney Neoplasms Tumors or cancers of the KIDNEY.	1.98	1
Carcinoma, Epidermoid [description not available]	1.97	1
Maxillary Neoplasms Cancer or tumors of the MAXILLA or upper jaw.	1.97	1
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	1.97	1

chemdatabank.com